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Abstract
Background: Rasburicase (FasturtecH or ElitekH, Sanofi-Aventis), the recombinant form of urate oxidase from Aspergillus
flavus, is a therapeutic enzyme used to prevent or decrease the high levels of uric acid in blood that can occur as a result of
chemotherapy. It is produced by Sanofi-Aventis and currently purified via several standard steps of chromatography. This
work explores the feasibility of replacing one or more chromatography steps in the downstream process by a crystallization
step. It compares the efficacy of two crystallization techniques that have proven successful on pure urate oxidase, testing
them on impure urate oxidase solutions.
Methodology/Principal Findings: Here we investigate the possibility of purifying urate oxidase directly by crystallization
from the fermentation broth. Based on attractive interaction potentials which are known to drive urate oxidase
crystallization, two crystallization routes are compared: a) by increased polymer concentration, which induces a depletion
attraction and b) by decreased salt concentration, which induces attractive interactions via a salting-in effect. We observe
that adding polymer, a very efficient way to crystallize pure urate oxidase through the depletion effect, is not an efficient
way to grow crystals from impure solution. On the other hand, we show that dialysis, which decreases salt concentration
through its strong salting-in effect, makes purification of urate oxidase from the fermentation broth possible.
Conclusions: The aim of this study is to compare purification efficacy of two crystallization methods. Our findings show that
crystallization of urate oxidase from the fermentation broth provides purity comparable to what can be achieved with one
chromatography step. This suggests that, in the case of urate oxidase, crystallization could be implemented not only for
polishing or concentration during the last steps of purification, but also as an initial capture step, with minimal changes to
the current process.
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Introduction
It is commonly recommended in the field of protein
crystallography that a protein solution be purified very thoroughly,
in order to maximize chances of successful crystallization.
However, crystallization is a technique that has itself long been
used in the purification of substances. It has been shown with
proteins that crystallization can occur from impure solutions [1,2],
which suggests that crystallization may be an efficient, fast and
cost-effective way to purify and concentrate a protein, as is already
done with small molecules.
In this paper, we investigate the possibility of using crystalliza-
tion as a purification step for a therapeutic enzyme, rasburicase,
the recombinant urate oxidase from Aspergillus flavus. Urate oxidase
(uricase, EC 1.7.3.3, uox) is a 135 kDa tetramer with identical
subunits having a molecular mass of about 34 kDa. It is
responsible for the first step in the degradation of uric acid to
allantoin. It is found in a variety of organisms, but its expression is
absent in humans and many primates, owing to several specific
mutations and deletions [3]. Such mutations may have had an
evolutionary function, as uric acid has antioxidant properties that
protect the body against neurological degenerative diseases and
age-related cancers [4]. Nevertheless, an accumulation of uric acid
can lead to gout and, in some extreme cases, to acute
hyperuricaemia. Consequently, urate oxidase is used as a
protein-based drug [5], FasturtecH (Sanofi-Aventis), a recombinant
urate oxidase (rasburicase) from Aspergillus flavus expressed in a
genetically modified Saccharomyces cerevisiae strain [6]. It is
prescribed to prevent renal failure in patients initiating chemo-
therapy due to rapid tumor lysis or shrinkage.
However, impurities introduced during the preparation of drugs
can lead to immunogenicity and hypersensitivity [7]. Using
rasburicase to replace pure urate oxidase extracted from Aspergillus
Flavus has dramatically decreased impurity in the drug and
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increased its specific activity [6]. To date, urate oxidase is purified
using multiple steps of concentration and chromatography [5]. In
the biopharmaceutical industry, purity requirements are very
stringent and the protein of interest undergoes several chromato-
graphic steps before it can be considered pure. The cell lines used
for the upstream process produce a high yield of protein, and the
large quantity of protein produced increases the feasibility of
crystallization in the downstream process, making it a good
candidate as an alternative to one or more of the chromatography
steps. As crystallization occurs more easily in pure solutions, it is
normally only considered for use as a polishing step at the end of
the downstream process. However, from a cost/efficiency point of
view, introducing it as a first step to extract and concentrate the
protein of interest from the fermentation broth would be
advantageous, since it can be performed inexpensively on very
large volumes.
Selecting the most appropriate crystallization methods for
protein purification is vital. A protein can be considered to be a
polyelectrolyte, meaning that a decrease in solubility via a pH shift
triggers crystallization and makes purification possible [8,9].
Adding salt can also be a very effective way to purify a protein
by crystallization via the salting-out effect [10–14]. It should be
noted that the salt used for purification is not necessarily the most
effective according to the Hofmeister series, probably because it is
chosen in order to decrease selectively the solubility of the protein
of interest without decreasing the solubility of the host cell
proteins. It has also been shown that the addition of a neutral and
non-absorbing polymer such as Poly Ethylene Glycol (PEG) can
purify a protein solution via the depletion effect [15–17]. Various
polymer sizes and concentrations have been used; however in
these cases the targeted proteins are usually of high molecular
weight (.100 kDa). Finally, a temperature shift could, in
principle, also be used as a crystallization method, but to our
knowledge there is no example of protein purification where
temperature per se triggers the crystallization. However, low
temperature plays an important role in preventing the protein
denaturation in a purification process where a change of solvent
induces crystallization [18].
Knowledge of the solubility of the protein of interest is one of
the main requirements in order to assess the use of crystallization
as a step in a downstream process. Indeed, a thorough study of
solubility is a prerequisite to the successful determination of the
crystallization conditions. But it also identifies suitable conditions
for crystal dissolution, if this is required in subsequent purification
steps. Determining solubility conditions avoids uncontrolled
precipitation, liquid-liquid phase separation or denaturation
during fermentation or concentration operations. Finally, solubil-
ity values determine the highest achievable crystallization yield: for
instance, if the protein concentration prior to crystallization is
10 mg/mL and the solubility after crystallization is 5 mg/mL, the
yield cannot exceed 50%; if the solubility after crystallization is
1 mg/mL, the yield could theoretically reach 90%. In principle, in
both cases, the protein contained in the supernatant could be
recycled in the next crystallization batch. This recycling may,
however, lead to quality issues. Thus, it would be preferable to
have low final solubility and obtain the highest possible yield in a
single batch.
The large number of structures available in the Protein Data
Bank, which have been determined by crystallography suggests
that many proteins can be crystallized. This raises the question of
why all the proteins of industrial interest with known crystalliza-
tion conditions are not purified via crystallization. A possible
explanation is that some of these crystallization conditions are not
compatible with a downstream process (additives which are not
pharmaceutically acceptable even in trace amounts; or which
decrease the biological activity of the protein; or which are too
expensive to be widely used). In addition, protein crystals generally
contain a lot of water (20 to 70%), and may therefore be too fragile
to be handled and separated from the supernatant. This water can
also contain impurities of lower molecular weight which would
decrease the effectiveness of the purification. Finally, protein
crystals are often small; they would need to be at least 20 mm in
size and to have a homogeneous size distribution in order to ease
the process of separation from the supernatant (by filtration or
centrifugation).
Results and Discussion
Crystallization of both pure extractive and recombinant urate
oxidase has been extensively studied [19–22], in particular via
thorough interaction potential studies [22–25]. It has been shown
that attractive interaction potentials between proteins in solution
drive the crystallization process [25–29]. Although urate oxidase
crystallizes under attractive conditions in the presence of polymer,
it can also crystallize under attractive conditions in Tris buffer
alone, without the addition of any crystallizing agents (salt or
polymer) [22]. In this latter case, its solubility is low (3 mg/mL)
and does not vary significantly with either temperature or with
pH, in the range where the tetrameric form of urate oxidase is
stable and active (Figure 1 A, B).
In contrast, the addition of salt in quantities of from a few mM
up to at least 1 M dramatically increases urate oxidase solubility
(Figure 1 C), which has been described as a strong salting-in effect
[22]. The difference is such that the protein is extremely soluble in
a 50 mM sodium phosphate buffer of pH 8 (at least 100 mg/mL),
whereas it is soluble only up to 3 mg/mL in a 50 mM Tris buffer
of pH 8 without any added salt. This difference is due the binding
of cations at four binding sites on the surface of the protein, which
changes its net charge thereby increasing repulsive interactions
and urate oxidase solubility. We have already shown that
decreasing salt concentration of a urate oxidase solution via
dialysis decreases protein solubility and is one way to trigger
crystallization. The crystal shape obtained also depends on the salt
used [22].
Another way to decrease urate oxidase solubility and trigger its
crystallization is to add common non-adsorbing polymers, such as
polyethylene glycols. Non-adsorbing polymers induce a depletion
attraction which favors crystallization [19,23,24]. We have also
recently shown [21] that, in the case of urate oxidase, effective
crystallization can be achieved by replacing the polyethylene
glycol 8000 by another nonionic polymer, namely poloxamer 188
(Figure 1 D). This amphiphilic polymer, similar in size to PEG
8000, is composed of two poly(oxyethylene) blocks and a central
poly(oxypropylene) block with a molecular weight of 8400 g/mol
and has a critical micellar concentration (cmc) of about 0.1% w/v
[30]. It acts, therefore, at low concentrations (below its cmc) as a
solubilizing agent, i.e. inducing repulsive interactions, and at high
concentrations (above its cmc) as a crystallizing agent, inducing
attractive interactions, without adverse effects on the protein
structure or activity [21]. As poloxamer 188 has been used for a
long time in the formulation of urate oxidase [31], we chose it over
PEG 8000 for crystallization trials.
In comparing these two strategies for crystallizing urate oxidase
from impure or partially purified solutions, it was thus vital to
respect the following conditions: i) The concentration of urate
oxidase prior to crystallization must be high enough, between 10
and 15 mg/mL, and the urate oxidase solubility after crystalliza-
tion lower than 3 mg/mL in order to reach a yield higher than
Purification by Crystallization
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70%; ii) Crystals must be sufficiently massive to be separated from
the supernatant. We have previously shown that the addition of
certain salts to the crystallization medium can induce the growth
of such crystals [22]. Since ammonium chloride is already present
in the buffer composition of the current urate oxidase purification
process by chromatography, it was chosen as a preferred salt; iii)
No substrate or inhibitor should be used. For example 8-
azaxanthine, a well-known competitive inhibitor [32], could not
be used in the crystallization conditions in this process despite the
fact that, by stabilizing the active site, it favors crystallization of
relatively massive good quality crystals.
The urate oxidase was sampled after each step of the
downstream process, referred to as pools 1 to 7, pool 1 being
the fermentation broth dialyzed and concentrated in Tris buffer
prior to the first chromatography step, pool 2 or 3, the solution
after the first chromatography step, and pool 7 the purest solution.
The different steps of the current process were analyzed by size
exclusion chromatography (SEC) (Figure 2), isoelectrofocusing
(IEF) (Figure 3) and activity assays. According to the gel filtration
column calibration where the active form of urate oxidase is a
135 kDa tetramer, the pool 1 chromatograph presents impurities
which are mainly aggregates with sizes higher than 670 kDa, large
proteins of roughly 230 kDa, probably urate oxidase octamers
(assessed by the activity test) and several unidentified host cell
proteins or degradation products of molecular weights lower than
135 kDa. The first chromatography step, which yields pools 2 and
3 in the current process, increases the urate oxidase purity up to
85% (assessed by SEC). The 15% of impurities remaining consist
mainly of urate oxidase octamers, as shown by their molecular
weight. The second step of chromatography, which yields pool 4,
purifies the urate oxidase further up to 99%. The last two
chromatography steps are polishing steps.
Despite these two polishing steps, the most purified form of
urate oxidase, i.e. pool 7, presents several isoforms (Figure 3)
identical to those found in pool 4,5 and 6. The IEF profile of pool
2, which is very similar to the IEF profile of pool 7, also suggests
that impurities observed present in this pool are modified forms of
urate oxidase. This is in agreement with the hypothesis supported
by the SEC data, which shows that pool 2 contains native urate
oxidase tetramers and urate oxidase octamers (double MW
according to the SEC calibration and similar IEF profile) and
no longer contains host cell proteins or aggregates of host cell
proteins.
These first results suggest that, implementing a crystallization
step in this purification process would have industrial advantages
at two stages. It would need to be introduced after the first
chromatography step (on pool 2 or 3), or preferably just before the
first chromatography step (on pool 1). To test this hypothesis, we
performed crystallization trials on both pool 1 and pool 3, this
latter differing from pool 2 only by an ultrafiltration step and a
Figure 1. Solubility variations of the recombinant urate oxidase. A) Solubility of urate oxidase as a function of pH in 50 mM Tris buffer at
20uC without added salt. B) Solubility of urate oxidase as a function of temperature in 50 mM Tris buffer pH 8, taking into account variation of pH as a
function of temperature with tris buffer (DpH/DT =20.03uC21). C) Solubility of urate oxidase as a function of salt type and ionic strength in 50 mM
Tris buffer pH 8 at 20uC. D) Solubility of urate oxidase as a function of polymer addition (PEG 8000 or Poloxamer P188) with and without salt at 20uC.
doi:10.1371/journal.pone.0019013.g001
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change in the nature of the buffer. First, poloxamer 188, above its
cmc, was added to urate oxidase pool 1. In pure solution of active
urate oxidase (pool 7), 100 mm well-defined crystals have
previously been obtained by a similar procedure [21]. Here, a
solid form was obtained, but it appeared more like a precipitate
than a crystal (Figure 4A). The precipitate was separated from the
supernatant by centrifugation and the supernatant was pipetted.
The precipitate was redissolved and SEC analysis (Figure 5A),
while showing fewer impurities than in urate oxidase pool 1,
indicates that the process is not as effective as the current
chromatography step 1. In particular, aggregates cannot be
removed. A decrease in proteins of low molecular weight is
observed, but this is revealed to be due to the ultrafiltration step
used to concentrate the solution prior to crystallization (data not
shown). IEF analysis shows that the protein extracted by adding
poloxamer presents the same IEF profile as pool 1, with slightly
less protein having acidic isoelectric points (Figure 6). The activity
test (Table 1) even shows only 25% of active protein retrievable,
against 63% activity in pool 1, and 85% after the first
chromatography step, which means that this procedure led to a
loss of activity. No improvement was observed when PEG 8000
was used instead of poloxamer 188 in this procedure (data not
shown).
Crystallization trials were next performed using reverse salt
dialysis (i.e. dialysis against the same buffer without salt) on urate
oxidase pool 1. In pure urate oxidase solution (pool 7), well-defined
50 mm-sized crystals have been previously obtained in this way
[22]. Here, 10 mm-sized solid forms were obtained. These are not
as well shaped as pure crystals, but they no longer appear like
precipitates (Figure 4B). These spherical protein particles (SPP)
were separated from the supernatant by centrifugation and the
supernatant was pipetted. The SPPs were redissolved and analysis
of the solution, analyzed by SEC, showed fewer impurities than in
pool 1, both for high molecular weight and low molecular weight
molecules (Figure 5B). The overall purity of the urate oxidase
obtained by reverse salt dialysis is comparable to what is obtained
with the current step 1 of chromatography from a SEC
perspective, even though the detailed profile differs in that it
contains less high molecular weight molecules but more low
molecular weight molecules. IEF confirms this result and shows
that a fraction of the remaining low molecular weight proteins
probably have acidic isoelectric points (Figure 6). The activity test
shows 85% of active proteins –retrievable against 63% activity in
pool 1 and 85% after the first chromatography step.
To investigate why adding polymer did not constitute an
adequate purification process for urate oxidase, the same
Figure 2. Size exclusion chromatography analysis of the 5
urate oxidase pools from the downstream process. Size
exclusion chromatography analysis of the 5 urate oxidase pools from
the downstream process. Each pool is analyzed on a Superdex 200 GL
column eluted in 50 mM sodium phosphate buffer pH 8 with UV-Vis
detection at 280 nm.
doi:10.1371/journal.pone.0019013.g002
Figure 3. IEF analysis of the 5 urate oxidase pools from the downstream process. IEF analysis of the 5 urate oxidase pools from the
downstream process. Pool 2/3 lane identical to that of pool 7, suggesting that the 230 kDa peak corresponds to octomers of urate oxidase.
doi:10.1371/journal.pone.0019013.g003
Purification by Crystallization
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procedure was performed on pool 3, i.e. partially purified urate
oxidase containing the active form (tetramer) and aggregates likely
to be urate oxidase octamers. Pool 3 contains the same impurities
as pool 2 and was chosen for crystallization experiments since, just
like pool 1, it is in a buffer more suitable for crystallization trials
(5 mM Tris pH 8.5, 0.1 mM EDTA). First, poloxamer 188 was
added to urate oxidase pool 3. 10 mm-sized solid forms were
obtained, not as well-shaped as crystals and appearing more like
precipitates (Figure 4C). These solid forms were separated from
the supernatant by centrifugation and the supernatant was
pipetted. Solid forms were redissolved, and analysis of the solution
by SEC, which showed that all impurities (octamers) are retained
and that the process is ineffective (Figure 5C).
A second crystallization trial was performed using reverse salt
dialysis of pool 3. 50 mm-sized well-shaped crystals were obtained
(Figure 4D). These crystals were separated from the supernatant
by centrifugation and the supernatant was pipetted. Crystals were
redissolved, and the solution analyzed by SEC, which showed
fewer impurities (octamers) than in pool 2 but still more than in
pool 4 (Figure 5D). The overall purity of the urate oxidase
obtained by reverse salt dialysis enables a decrease in octamer
concentration, but is not as effective as the current second
chromatography step.
These experiments on pool 3 confirm that adding polymer is
less effective than reverse salt dialysis for purifying urate oxidase.
Urate oxidase octamers and other type of aggregates seem to be as
sensitive as urate oxidase to the depletion effect induced by
polymer, thus explaining its lack of selectivity. Moreover, the
strong salting-in effect exhibited by urate oxidase seems to be
present to a lower extent in urate oxidase octamers, and absent in
other types of aggregates and host cell proteins, which explains
how purification can be achieved by this means.
Overall, then, in the case of urate oxidase, purification based on
salting-in crystallization is shown to be more effective than that by
adding polymer. If the SEC results were confirmed by orthogonal
analytical techniques, the purity of the protein obtained by
crystallization in a low ionic strength buffer would challenge what
is currently achieved with a first step of chromatography. This
method can therefore be implemented during the current
purification process with minimal process changes, since urate
oxidase pool 1 is currently buffered at a low ionic strength (5 mM
Tris pH 8.5; 0.1 mM EDTA) and the protein content (urate
Figure 4. Crystallization trials of urate oxidase from pool 1 and pool 3 either via addition of poloxamer or via reverse dialysis.
Crystallization trials of urate oxidase from pool 1 and 3. Top) Crystallization conditions of pool 1. A) cUOx<35 mg/mL, 5% poloxamer 188, NH4Cl
20 mM, Tris 5 mM pH 8.5. B) cUOx<40 mg/mL, Tris 5 mM pH 7.5, 20 mM NH4Cl vs. Tris 5 mM pH 7.5. Bottom) Crystallization of pool 3. C)
cUOx<11 mg/mL, 2.5% poloxamer 188, NH4Cl 45 mM, Tris 50 mM pH 7.5. D) cUOx<68 mg/mL 100 mM NH4Cl, Tris 50 mM pH 7.5 vs. Tris 50 mM
pH 7.5.
doi:10.1371/journal.pone.0019013.g004
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oxidase active form and impurities) is around 15 mg/mL. As the
solubility of the active form of urate oxidase is 2 mg/mL (+/2
1 mg/mL) in these conditions, urate oxidase pool 1 is supersat-
urated and should eventually crystallize. In our experiment, when
pool 1 was stored at 5uC, crystals were found to appear over time.
Well-defined 20 mm-sized crystals were harvested after 1 month of
storage (Figure 7, top) and a purity of 87%was assessed by SEC
after redissolution of the crystals (Figure 7, bottom), which is
comparable to what is obtained by the current first chromatog-
raphy step. Further studies with a focus on nucleation kinetics are
now needed to determine how this process can be improved (yield,
crystal size distribution, robustness) scaled-up and accelerated: for
instance, by seeding the solution with pure urate oxidase crystal
fragments or by concentrating the solution to increase the
nucleation rate.
Summary
High-resolution crystallography techniques require crystalliza-
tion of very pure macromolecules, and the present study confirms
that crystallization is itself a relatively effective purification step, its
efficacy depending primarily on the crystallization method used.
Adding polymers to a solution of macromolecules can lead to its
crystallization by depletion attraction between macromolecules.
However this attractive interaction is more effective with large
molecules, and adding polymer (poloxamer or polyethylene glycol)
to urate oxidase solutions, either on the crude extract from
fermentation broth or on the partially purified solutions, does not
lead to satisfactory crystallization. Purification by this crystalliza-
tion method is not as effective as a chromatography step, although
it has been shown to be a very effective method for crystallization
of pure protein solutions. This is probably due to the fact that large
host cell proteins and urate oxidase aggregates are just as sensitive
to the entropic depletion effect induced by high concentrations of
poloxamer 188 and PEG 8000 as urate oxidase. The non-specific
effect of polymers thus makes this crystallization method
insufficiently selective for use as a purification step. In contrast,
salts induce a more specific attraction on macromolecules in
solutions [33]. Using salting-in and salting-out effects for
purification by crystallization leads to very effective purification.
Most proteins are sensitive to salting-out and this effect has been
Figure 5. Size exclusion chromatography analysis of urate oxidase crystal content versus chromatography steps 1 and 2. (top) SEC
analysis of the crystal content of urate oxidase from pool 1 (unfilled cross) compared to pool 1 (filled circle) and pool 2 (unfilled square): crystallization
conditions were (left) 35 mg/mL urate oxidase with 5% poloxamer 188 in 5 mM Tris pH 8.5, 50 mM NH4Cl; (right) 40 mg/mL urate oxidase in 5 mM
Tris pH 8.5, 50 mM NH4Cl, dialyzed against Tris 5 mM pH 8; (bottom) SEC analysis of the crystal content of urate oxidase from pool 3 (unfilled cross)
compared to pool 2 (unfilled square) and pool 4 (crossed square): crystallization conditions were (left) 11 mg/mL urate oxidase with 2.5% poloxamer
188 in 5 mM Tris pH 8.5, 50 mM NH4Cl; (right) 68 mg/mL urate oxidase in 5 mM Tris pH 8.5, 50 mM NH4Cl, dialyzed against 5 mM Tris pH 8.
doi:10.1371/journal.pone.0019013.g005
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extensively studied [34–36] and used. The salting-in effect has only
sporadically been used for crystallization [37], because this effect
does not apply to all proteins [38]. Previous fundamental studies
performed on pure urate oxidase and other proteins [22,24,39]
revealed the nature of the interparticle forces which control the
properties of macromolecule solutions and therefore their phase
diagrams, and which ultimately generate crystals. Due to its strong
salting-in effect, urate oxidase can be purified by crystallization
from pool 1 as effectively as by current chromatography steps, at
least from an SEC perspective.
This study therefore reveals that a crystallization approach to
purification offers advantages in developing efficient industrial
processes and reducing costs. Similar investigations on other
readily available proteins of industrial interest should reveal the
specific crystallization conditions relevant in each case.
Materials and Methods
Solutions
Solutions of recombinant urate oxidase (pool 1 to pool 7) were
collected at different steps of the downstream process, which
consists of four standard steps of chromatography (ion exchange,
hydrophobic and gel filtration). In between these chromatography
steps, ultrafiltration and diafiltration are also performed to
Figure 6. IEF analysis of the urate oxidase after crystallization. IEF analysis of the urate oxidase. From top to bottom: a) pool 1 ; b) pool 1
after 50 mM NH4Cl addition and ultrafiltration, c) crystal content from 35 mg/mL urate oxidase pool 1 with 5% poloxamer 188 in 5 mM Tris pH 8.5,
50 mM NH4Cl; d) supernatant from 35 mg/mL urate oxidase pool 1 with 5% poloxamer 188 in 5 mM Tris pH 8.5, 50 mM NH4Cl; d) pool 7 ; e) crystal
content from 40 mg/mL urate oxidase pool 1 in 5 mM Tris pH 8.5, 50 mM NH4Cl, dialyzed against 5 mM Tris pH 8; f) supernatant from 40 mg/mL
urate oxidase pool 1 in 5 mM Tris pH 8.5, NH4Cl 50 mM, dialyzed against 5 mM Tris pH 8, g) pool 7.
doi:10.1371/journal.pone.0019013.g006
Table 1. Efficacy of each technique in terms of % recovery.
SEC (±2%) IEF (±10%) Activity (±5%)
280 nm 226 nm
Pool 1 51% 78% 45% 63%
Pool 2 85% 84% 65% 85%
From pool 1 crystals with poloxamer 188 67% 75% 47% 25%
From pool 1 crystals by reverse dialysis 90% 93% 70% 85%
Spontaneous pool 1 crystals 87% 96% n.d. n.d.
Pool 3 85% 84% 65% 85%
Pool 4 100% 100% 100% 100%
From pool 3 crystals with poloxamer 188 85% 84% 50% 98%
From pool 3 crystals by reverse dialysis 93% 92% 90% 100%
Comparison of the three techniques of purification, chromatography, crystallization by poloxamer addition, and crystallization by reverse dialysis in terms of % recovery
of protein and activity.
n.d. not determined.
doi:10.1371/journal.pone.0019013.t001
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concentrate the protein and exchange buffers. For reasons of
confidentiality with regard to the current production process,
details of columns and buffers cannot be disclosed.
1 M ammonium chloride and 0.015 mg/mL uric acid stock
solutions were prepared by dilution of the appropriate quantity of
the two salts (purchased from Sigma-Aldrich) in 50 mM Tris-HCl
buffer, pH 8 (+/2 0.5 pH unit).
25% w/v= poloxamer 188 (from powder supplied by BASF)
and 40% PEG 8000 (from 50% solution supplied by Hampton
research) solutions were also prepared in 50 mM Tris buffer,
pH 8.
All salt and urate oxidase solutions for crystallization trials were
filtered through 0.22 mm Millipore filters.
Size Exclusion Chromatography (SEC)
Size Exclusion Chromatography analyses were performed on a
GE Healthcare AKTA basic system with a Superdex 200 GL
column eluted in 50 mM sodium phosphate buffer pH 8. Seven
proteins of molecular weights ranging from 13.7 kDa to 669 kDa
were used to calibrate the column (ribonuclease, chymotrypsine,
ovalbumine, aldolase, catalase, ferritine and thyroglobuline).
Protein was detected by UV absorbance at 226 nm and 280 nm.
Isoelectrofocusing (IEF)
All reagents were purchased from BIO-RAD: Criterion ready
gel pH 5–8 and 3–10; 10 x anode buffer, 7 mM phosphoric acid;
10x cathode buffer 20 mM lysine, 20 mM arginine; sample buffer:
50% glycerol; gel stain Coomassie R-250/Crocein Scarlet and
protein standard consisting of a mixture of nine native proteins
with isoelectric points ranging from 4.45 to 9.6 (cytochrome c,
lentil lectin, human hemoglobin C and A, equine myoglobin,
human and bovine carbonic anhydrase, beta lactoglobulin B and
phycocyanin). Twenty microliters of each sample (approximately
at 1 mg/mL) were uploaded into the wells of the gel and power
was applied (100 V constant for the first hour then 250 V constant
for one hour and finally 500 V constant for 30 min). The gel was
then bathed in the Coomassie staining solution for 45 min and
washed overnight in the destaining solution (400 mL of 100%
methanol, 500 mL of deionized water, +and 100 mL of glacial
acetic acid).
Biological activity test
The enzymatic activity of the urate oxidase was determined by
monitoring the degradation of uric acid at 292 nm. Urate oxidase
crystals grown either via salt dialysis or via polymer addition were
dissolved in a solution of 50 mM Tris, pH 8, 100 mM KCl. The
protein concentration was measured by UV absorbance at
280 nm, using an extinction coefficient of 1.69 mL.mg21cm21.
The urate oxidase activity was determined by measuring the initial
consumption rate of uric acid by spectrophotometry: 561025 mg
of urate oxidase was added to 6 mg of uric acid in 50 mM tris-HCl,
pH 8.5, and the variation in concentration of the uric acid was
monitered at 292 nm using an extinction coefficient of 12.2 mol21
cm21. The initial consumption rate, expressed in mol.min21, was
then normalized by the quantity of urate oxidase introduced (in
mg) to obtain the specific activity of the enzyme. The experiment
was repeated using two other concentrations of urate oxidase to
correlate specific activity values.
Crystallization trials
In Tris buffer, in the presence of 50 mM NH4Cl, pure urate
oxidase is known [22] to be soluble to at least 100 mg/mL. NH4Cl
was therefore added to impure urate oxidase solution from pools 1
or 3, to a final concentration of about 50 mM. These solutions
were then concentrated to 50 mg/mL by ultrafiltration in a
10 mL Amicon cell using a 30 kDa cut-off membrane. Crystal-
lization was performed either by adding poloxamer 188 to a final
concentration of 2.5 to 4% or by dialyzing the solutions against
5 mM Tris pH 8 without salt using a 300 mL Spectra/Por Float-a-
lyzer. In both cases, the solid phase (crystal or precipitate) obtained
in batch after 12 h was separated from the supernatant by
centrifugation and extraction of the supernatant by pipetting. The
solid phase was redissolved in a 50 mM Tris pH 8, 100 mM KCl
prior to analysis (SEC, IEF, activity test).
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Figure 7. Spontaneaous urate oxidase crystals from pool 1 at
56C (top) and SEC analysis (bottom). Top: Urate oxidase crystals
grown spontaneously in pool 1 after one month’s storage at 5uC.
Bottom: SEC analysis of this urate oxidase crystal content grown in pool
1 after one month storage at 5uC (filled square) and comparison with
crystals obtained after reverse dialysis from pool 1 (unfilled cross) and
chromatography from pool 2 (unfilled square).
doi:10.1371/journal.pone.0019013.g007
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